Acclinate uses predictive analytics and machine learning to source diverse leads who are likely to participate in your clinical trial.
Request A Demo
e-DICT uses predictive analytics and machine learning to know who to ask, when to ask, and how to ask for clinical trial participation. e-DICT accelerates the process of meeting your recruitment goals of time, cost, and diversity.
Reduce Recruitment Time
e-DICT uses predictive analytics to target likely participants within communities of color quickly and efficiently.
Reduce Recruitment Costs
e-DICT lowers patient recruitment costs by providing real-time reports that allow you to optimize your recruitment funnel.
Increase Diversified Participation
e-DICT participant data comes primarily from communities of color where participation and knowledge of clinical research are high.
No specialized training needed
Adheres to your approved IRB protocols
Robust tracking and reporting
Participation Probability Index (PPI)
e-DICT analyzes your trial characteristics against our diverse health and engagement data to find qualified individuals most likely to enroll in your trial. Likely participants are then made aware of your trial so they can make an informed decision about enrolling.
e-DICT provides real-time reports so you can track progress from awareness to engagement to participation.
By combining our deep understanding and engagement of minority communities with e-DICT, we deliver clinical trial leads who are:
"Trust is driven by relationships. The key to diversity is inclusion, we strive to include minorities in conversations, not as a statistic, as a human being."
Tiffany Whitlow
Co-Founder, COO
Acclinate
“We partnered with Acclinate because their platform and services will lead to successful recruitment and engagement of study participants for our first of its kind, ARGONAUT study.”
Stephanie Culler, Ph.D.
Co-Founder, CEO
Persephone Biosciences, Inc.
“Acclinate is at the forefront of implementing a portal to make certain minorities are included in clinical trials.”
Randall Moreadith, MD, PhD
President
Serina Therapeutics
